Phase II trial of thalidomide in refractory/relapsed diffuse large B-cell lymphoma and Hodgkin's disease

Trial Profile

Phase II trial of thalidomide in refractory/relapsed diffuse large B-cell lymphoma and Hodgkin's disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 May 2009

At a glance

  • Drugs Thalidomide (Primary)
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 May 2009 Additional lead trial investigator Heffner LT identified as reported by ClinicalTrials.gov.
    • 12 May 2009 Actual patient number (2) added as reported by ClinicalTrials.gov.
    • 14 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top